Related Experiment Videos
Concerns regarding lamotrigine and breast-feeding
Joyce Liporace1, Amy Kao, Anelyssa D'Abreu
1Department of Neurology, Jefferson Medical College, Philadelphia, PA, USA. Joyce.Liporace@jefferson.edu
Epilepsy & Behavior : E&B
|January 31, 2004
Summary
Newborns of mothers with epilepsy on lamotrigine (LTG) may have higher-than-expected drug levels due to immature metabolism. Monitoring LTG in breast-fed infants is recommended.
Area of Science:
- Pharmacology
- Neonatal Metabolism
- Epilepsy Treatment
Background:
- Lamotrigine (LTG) is a common epilepsy medication for pregnant women.
- Current guidelines recommend breastfeeding for mothers with epilepsy.
- Neonatal drug metabolism, particularly glucuronidation, is immature.
Purpose of the Study:
- To determine lamotrigine (LTG) levels in nursing newborns.
- To assess LTG metabolism in neonates exposed via breastfeeding.
- To inform breastfeeding recommendations for mothers with epilepsy on LTG.
Main Methods:
- Serum LTG levels measured in mothers and neonates on Day 10 of life.
- Maternal LTG clearance assessed during pregnancy and postpartum.
- Correlation of maternal and neonatal LTG levels.
Main Results:
- Neonatal LTG levels ranged from <1.0 to 2.0 microg/mL.
- Newborn LTG levels were approximately 30% of maternal levels.
- No significant decline in LTG levels observed by 2 months in two infants.
Conclusions:
- Breastfed neonates can have unexpectedly high lamotrigine (LTG) levels.
- Immature neonatal glucuronidation likely contributes to LTG accumulation.
- Individualized counseling and monitoring of LTG levels in infants are warranted.